Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

DBV Technologies (DBV)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.26 +0.01    +0.48%
08:40:53 - Real-time Data. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  France
ISIN:  FR0010417345 
  • Volume: 31,984
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 1.25 - 1.29
DBV Technologies 1.26 +0.01 +0.48%

DBV Technologies Company Profile

 
Get an in-depth profile of DBV Technologies, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

105

Equity Type

ORD

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Contact Information

Address 177-181 Avenue Pierre Brossolette
Montrouge, 92120
France
Phone 33 1 55 42 78 78
Fax 33 1 43 26 10 83

Top Executives

Name Age Since Title
Pierre-Henri Benhamou 66 2002 Co-Founder & Member of Scientific Advisory Board
Gideon Lack - - Member of the Scientific Advisory Board
Jonathan M. Spergel - - Member of the Scientific Advisory Board
Michael Rosenblum - 2019 Member of Scientific Advisory Board
Christophe Dupont - - Member of Advisory Board
Ravi Madduri Rao 55 2021 Independent Director
Emma Guttman-Yassky - 2019 Member of Scientific Advisory Board
Jim Krueger - 2019 Member of Scientific Advisory Board
Miriam Merad - 2019 Member of Scientific Advisory Board
Jean-François Nicolas - 2019 Member of Scientific Advisory Board
Adora Ndu 41 2021 Independent Director
Betty A. Diamond - 2021 Member of Scientific Advisory Board
Daniele Guyot-Caparros 64 2022 Independent Director
Michel de Rosen 72 2018 Independent Chairman of the Board
Hugh A. Sampson 74 2015 Scientific Adviser to the CEO & Chairman of Scientific Advisory Board
Michael J. Goller 48 2015 Director
Daniel Tassé 63 2018 CEO & Director
Mailys Ferrere 61 2012 Director
Paul-Henri Lambert 84 - Member of the Scientific Advisory Board
Daniel B. Soland 67 2015 Independent Director
Timothy E. Morris 62 2021 Independent Director
Julie O'Neill 57 2017 Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

DBV Comments

Write your thoughts about DBV Technologies
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
João Catarino
João Catarino Feb 11, 2021 11:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://finance.yahoo.com/news/notice-media-covid-19-july-120000875.html?.tsrc=fin-srch
Krava Tsakosh
Krava Tsakosh Jan 18, 2021 8:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
FDA will approve it...
Krava Tsakosh
Krava Tsakosh Jan 18, 2021 8:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
DBV Technologies price target raised to $7 from $4 at Goldman Sachs. Goldman Sachs analyst Graig Suvannavejh raised the firm's price target on DBV Technologies (DBVT) to $7 from $4 and keeps a Buy rating on the shares after the company announced an update on the U.S. regulatory status of lead asset Viaskin Peanut. The stock closed Friday up 51% to $5.66. The analyst came away "increasingly positive" given the clarity gained on the forward, and continues to have confidence in the ultimate approvability of Viaskin Peanut in the U.S. and its commercial potential. Viaskin Peanut is the more attractive and easier product to administer relative to its main competition, Nestle's (NSRGY) Palforzia, Suvannavejh tells investors in a research note.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email